JPH0920684A - Chewing gum - Google Patents
Chewing gumInfo
- Publication number
- JPH0920684A JPH0920684A JP7196098A JP19609895A JPH0920684A JP H0920684 A JPH0920684 A JP H0920684A JP 7196098 A JP7196098 A JP 7196098A JP 19609895 A JP19609895 A JP 19609895A JP H0920684 A JPH0920684 A JP H0920684A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- egg
- chewing gum
- egg antibody
- chicken
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015218 chewing gum Nutrition 0.000 title claims abstract description 57
- 229940112822 chewing gum Drugs 0.000 title claims abstract description 57
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 22
- 208000015181 infectious disease Diseases 0.000 claims abstract description 17
- 230000002265 prevention Effects 0.000 claims abstract description 16
- 244000005700 microbiome Species 0.000 claims abstract description 15
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 4
- 210000000991 chicken egg Anatomy 0.000 claims description 58
- 208000023504 respiratory system disease Diseases 0.000 claims description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 10
- 239000013566 allergen Substances 0.000 claims description 7
- 206010048685 Oral infection Diseases 0.000 claims description 6
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 235000013601 eggs Nutrition 0.000 abstract description 101
- 238000000034 method Methods 0.000 abstract description 34
- 210000002969 egg yolk Anatomy 0.000 abstract description 28
- 102000002322 Egg Proteins Human genes 0.000 abstract description 25
- 108010000912 Egg Proteins Proteins 0.000 abstract description 25
- 235000013345 egg yolk Nutrition 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 22
- 239000000843 powder Substances 0.000 abstract description 19
- 241000194019 Streptococcus mutans Species 0.000 abstract description 8
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 6
- 102000018358 immunoglobulin Human genes 0.000 abstract description 6
- 230000009849 deactivation Effects 0.000 abstract 1
- 230000029087 digestion Effects 0.000 abstract 1
- 210000003437 trachea Anatomy 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 32
- 235000009508 confectionery Nutrition 0.000 description 29
- 244000299461 Theobroma cacao Species 0.000 description 24
- 235000019219 chocolate Nutrition 0.000 description 23
- 241000700605 Viruses Species 0.000 description 19
- 210000000214 mouth Anatomy 0.000 description 15
- 241000606125 Bacteroides Species 0.000 description 14
- 241000287828 Gallus gallus Species 0.000 description 13
- 235000013330 chicken meat Nutrition 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000002504 physiological saline solution Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 208000028169 periodontal disease Diseases 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000002649 immunization Methods 0.000 description 8
- 230000001055 chewing effect Effects 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 208000002925 dental caries Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- 241000702670 Rotavirus Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- 241000186044 Actinomyces viscosus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000010634 bubble gum Nutrition 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- -1 furceleran Polymers 0.000 description 2
- 108010052221 glucan synthase Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000018984 mastication Effects 0.000 description 2
- 238000010077 mastication Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 229940013390 mycoplasma pneumoniae Drugs 0.000 description 2
- 239000000025 natural resin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229920003051 synthetic elastomer Polymers 0.000 description 2
- 239000005061 synthetic rubber Substances 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241000203231 Breda virus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 244000281762 Chenopodium ambrosioides Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 240000005109 Cryptomeria japonica Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588754 Klebsiella sp. Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241001135223 Prevotella melaninogenica Species 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241000219053 Rumex Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000005496 tempering Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、感染症又は呼吸器
系疾患を予防するチューインガムに関し、より詳しく
は、感染症の原因微生物又は呼吸器系疾患のアレルゲン
に特異的な鶏卵抗体を含有するチューインガムに関す
る。TECHNICAL FIELD The present invention relates to chewing gum for preventing infectious diseases or respiratory diseases, and more particularly to chewing gum containing an egg antibody specific to the causative microorganism of infectious diseases or the allergen of respiratory diseases. Regarding
【0002】[0002]
【従来の技術及び発明が解決しようとする課題】近年、
様々な感染症による発病が問題になっており、その感染
症に対する予防方法として受動免疫の考えがある。その
受動免疫には、食品である卵から抽出される鶏卵抗体を
利用する方法が有効である。口腔内感染症であるう蝕に
おける受動免疫の従来技術としては、例えば以下のよう
なものがある。特開平1−242534号公報、特開平
1−190635号公報、特開平3−279398号公
報には、う蝕の原因菌、グルカン、及び菌体外酵素で鶏
に免疫し、その鶏より得られた卵より精製された鶏卵抗
体を利用する方法が記載されている。例えば、S.mutans
には血清型がa〜hまでの8種類が知られているが、特
公昭63−15247号公報には、抗原として血清型
a,b,c,dのS.mutansの菌体を用いた混合抗原で免
疫した牛の母乳から得た抗体でう蝕を予防する方法が記
載されている。また特開平1−242534号公報、特
開平1−190635号公報、特開平1−233299
号公報、特開平1−226828号公報には、血清型
c,e,fのS.mutans菌体結合型グルコシルトランスフ
ェラーゼあるいは、血清型c,e,fのS.mutansの水溶
性グルカン合成酵素あるいは血清型a,d,gのS.muta
nsの非水溶性グルカン合成酵素、あるいは血清型c,
e,fのS.mutans菌体表層タンパク質抗原で免疫した鶏
が産生する卵より精製した抗体を含むう蝕予防剤等が記
載されている。2. Description of the Related Art In recent years,
Onset of various infectious diseases has become a problem, and passive immunity is considered as a preventive method against the infectious diseases. For the passive immunization, a method using an egg egg antibody extracted from the food egg is effective. Examples of conventional techniques for passive immunity in dental caries, which is an oral infection, include the following. JP-A-1-242534, JP-A-1-190635, and JP-A-3-279398 disclose that a carcass-causing bacterium, glucan, and extracellular enzyme are used to immunize a chicken and the chicken is immunized. A method of using a chicken egg antibody purified from roe eggs is described. For example, S.mutans
8 types of serotypes from a to h are known, but Japanese Patent Publication No. 63-15247 uses S. mutans cells of serotypes a, b, c and d as antigens. A method for preventing caries with antibodies obtained from the milk of cows immunized with mixed antigens is described. Further, JP-A-1-242534, JP-A-1-190635, and JP-A-1-233299.
JP-A No. 1-226828 and S. mutans cell-bound glucosyltransferase of serotype c, e, f, or water-soluble glucan synthase of S. mutans of serotype c, e, f or S. muta of serotypes a, d, g
ns water-insoluble glucan synthase, or serotype c,
A caries preventive agent and the like containing antibodies purified from eggs produced by chickens immunized with the S. mutans cell surface protein antigens e and f are described.
【0003】歯周炎や歯槽膿漏等の歯周病疾患は多くの
人々が罹患しており、特に成人の罹患率は上昇の一途を
たどっている。そこで、今後老齢化が進む中で歯周疾患
の予防は重要な課題である。歯周疾患を防止するには、
歯周病原因菌の口腔内の定着を予防することが重要であ
り、歯周病原因菌に対する特異抗体を用いた各種の方法
が試みられている。例えば、バクテロイデス・ジンジバ
リウス(Bacteroides gingivalis)、アクチノバチルス
・アクチノマイセテムコミタンス(Actinobacillus act
inomycetemcomitans)及びアクチノマイセス・ビスコー
サス(Actinomyces viscosus)から選ばれる歯周病原因
菌の全菌体、線毛または莢膜を抗原として哺乳類に免疫
し、その動物の血清または乳より得られる抗体と界面活
性剤とが配合されている口腔用組成物(特公平6−99
291号公報、特公平6−99292号公報)や、歯周
病の原因菌をメン鶏に免疫し、その過免疫したメン鶏が
産生する卵の卵黄より得られる抗体による抗歯周病組成
物(特開平1−313438号公報)等が知られてい
る。Periodontal diseases such as periodontitis and alveolar pyorrhea are affected by a large number of people, and the morbidity rate of adults in particular is increasing. Therefore, prevention of periodontal disease is an important issue as the population ages in the future. To prevent periodontal disease,
It is important to prevent colonization of periodontal disease-causing bacteria in the oral cavity, and various methods using specific antibodies against periodontal disease-causing bacteria have been tried. For example, Bacteroides gingivalis, Actinobacillus actinomycetemcomitans
inomycetemcomitans) and Actinomyces viscosus (actinomyces viscosus) are selected from the whole body of periodontal disease-causing bacteria, pili or capsule to immunize mammals as antigens, and the antibodies and interfaces obtained from the serum or milk of the animals Composition for oral cavity containing active agent (Japanese Patent Publication No. 6-99
No. 291 and Japanese Patent Publication No. 6-99292), and an anti-periodontal disease composition by an antibody obtained from the yolk of an egg produced by immunizing a chicken with periodontal disease-causing bacteria and producing the hyperimmunized chicken. (Japanese Patent Laid-Open No. 1-313438) and the like are known.
【0004】気管又は気道感染症の原因菌またはウイル
スにおける受動免疫については、インフルエンザウイル
ス、バクテリア、マイコプラズマ及びリケッチアを鶏に
免疫し、その鶏より得られた卵より精製された鶏卵抗体
を利用する報告、またアレルギーの原因である花粉やダ
ニ等に対する鶏卵抗体を利用する報告がある(特開昭6
2−175426号公報)。かかる鶏卵抗体をスプレー
剤として用いることにより、気道に吸着した病原体を中
和し、呼吸器系疾患を予防する方法が試みられている。Regarding passive immunization against a causative bacterium or virus of tracheal or respiratory tract infection, a report is reported in which chicken eggs are immunized with influenza virus, bacteria, mycoplasma and rickettsia and chicken egg antibodies purified from eggs obtained from the chickens are used. In addition, there is a report using an egg egg antibody against pollen, mites, etc., which cause allergies (Japanese Patent Laid-Open No. 6-58242).
2-175426). A method of neutralizing pathogens adsorbed in the respiratory tract and preventing respiratory diseases by using such an egg egg antibody as a spray has been attempted.
【0005】消化管感染症の原因菌又はウイルスにおけ
る受動免疫については、胃炎、胃又は十二指腸潰瘍の原
因であるヘリコバクター・ピロリーに対する鶏卵抗体
(特開平4−275232号公報)及びロタウイルスに
対する鶏卵抗体を利用する報告がある(特開平1−26
5034号公報、特開平4−178335号公報)。消
化管感染症の原因菌またはウイルスは、消化管粘膜に付
着感染し、消化管細胞にダメージを与え、その結果下痢
を発症させる。これらの消化管感染症の原因菌またはウ
イルスに特異的な鶏卵抗体により、消化管への付着及び
感染が抑制されることはすでに見出されている(特開平
1−265034号公報)。かかる微生物は経口感染す
るものが多く、そのため口腔内にて当該微生物に特異的
な鶏卵抗体を存在させておくことは、感染症予防にとっ
て効果的である。Regarding passive immunization against a causative bacterium or virus of gastrointestinal tract infection, chicken egg antibodies against Helicobacter pylori (Japanese Patent Laid-Open No. 4-275232) and rotavirus against rotavirus, which cause gastritis, stomach or duodenal ulcer, can be used. There is a report to use (JP-A-1-26)
5034, JP-A-4-178335). The causative bacterium or virus of the digestive tract infection adheres to the digestive tract mucosa and damages the digestive tract cells, resulting in diarrhea. It has already been found that adhesion to the gastrointestinal tract and infection are suppressed by hen egg antibodies specific to the causative bacteria or viruses of these gastrointestinal tract infections (Japanese Patent Laid-Open No. 1-265034). Since many of these microorganisms are orally infected, it is effective for the prevention of infectious diseases to make the hen egg antibody specific to the microorganism exist in the oral cavity.
【0006】上述のように、鶏卵抗体を感染症予防や呼
吸器系疾患予防に利用する試みは行われているものの、
鶏卵抗体が口腔内に滞留する時間が一時的であるため、
鶏卵抗体の効果の持続性及び摂取の容易性に問題があっ
た。即ち、受動免疫により感染症を予防するには原因菌
に対する抗体を継続して摂取する必要がある。そのため
には、鶏卵抗体を含有する基材が長時間その効果を保持
することが求められる。また、摂取が容易であること
も、感染症の予防には必要なことである。また、鶏卵抗
体は熱やpHに対して不安定であるため、鶏卵抗体に高
温や強酸性および強アルカリ性の処理を施すことはでき
ない。例えば、鶏卵抗体をキャラメルやキャンディーに
添加する場合、キャラメルやキャンディーの製造時の温
度が120℃以上となるため抗体活性が失活する恐れが
ある。また、鶏卵抗体をラムネ菓子に添加する場合、ラ
ムネ菓子にはクエン酸や酒石酸を添加しているため溶解
時にpHが強酸となり抗体活性が失活してしまう恐れが
ある。そこで、抗体活性の失活を抑え、抗体の効果を充
分発揮できるような基材についても求められている。As mentioned above, although attempts have been made to utilize chicken egg antibodies for the prevention of infectious diseases and respiratory diseases,
Because the egg egg antibody stays in the oral cavity temporarily,
There was a problem in the persistence of the effect of the egg yolk antibody and the ease of ingestion. That is, in order to prevent infectious diseases by passive immunity, it is necessary to continuously ingest antibodies against the causative bacteria. For that purpose, it is required that the substrate containing the egg egg antibody retains its effect for a long time. Also, the ease of ingestion is necessary for the prevention of infectious diseases. Further, since the egg egg antibody is unstable to heat and pH, the egg egg antibody cannot be subjected to high temperature, strong acid or strong alkaline treatment. For example, when a chicken egg antibody is added to caramel or candy, the temperature during the production of caramel or candy becomes 120 ° C. or higher, and thus the antibody activity may be inactivated. In addition, when the chicken egg antibody is added to the Ramune confectionery, citric acid or tartaric acid is added to the Ramune confectionery, so that the pH becomes a strong acid at the time of dissolution and the antibody activity may be inactivated. Therefore, there is also a demand for a base material capable of suppressing the inactivation of antibody activity and sufficiently exerting the effect of the antibody.
【0007】本発明の目的は、かかる課題を解決すべ
く、鶏卵抗体の効果が長時間持続し、摂取が容易であ
り、かつ製造時に鶏卵抗体が失活しないような基材を用
いた鶏卵抗体含有食品を提供することにある。In order to solve the above problems, an object of the present invention is to use an egg egg antibody using a base material in which the effect of the egg egg antibody lasts for a long time, is easy to ingest, and does not deactivate the egg egg antibody during production. To provide food containing.
【0008】[0008]
【課題を解決するための手段】本発明者らは、前記課題
を解決するため鋭意研究した結果、鶏卵抗体を添加する
基材としてチューインガムを用いることにより、即ち、
チューインガムに鶏卵抗体を含有させることにより、鶏
卵抗体の効果の持続性の長時間化、摂取の容易化、及び
失活の防止を達成できることを見出し、本発明を完成す
るに至った。Means for Solving the Problems The inventors of the present invention have conducted extensive studies to solve the above problems, and as a result, by using chewing gum as a base material to which an egg egg antibody is added, that is,
The present invention has been completed by discovering that the chicken egg antibody can be contained in chewing gum for a long duration of effect of the egg egg antibody, facilitation of ingestion, and prevention of inactivation.
【0009】即ち、本発明の要旨は、(1) 鶏卵抗体
を感染症予防の有効成分として含有するチューインガ
ム、(2) 鶏卵抗体が口腔内感染症の原因微生物に対
する抗体、気管又は気道感染症の原因微生物に対する抗
体、及び消化管感染症の原因微生物に対する抗体からな
る群より選ばれる1種以上のものである前記(1)記載
のチューインガム、(3) 鶏卵抗体を呼吸器系疾患予
防の有効成分として含有するチューインガム、(4)
鶏卵抗体が呼吸器系疾患のアレルゲンに対する抗体であ
る前記(3)記載のチューインガム、並びに(5) 鶏
卵抗体を純品換算で0.01〜10重量%含有してなる
前記(1)〜(4)いずれか記載のチューインガム、に
関するものである。That is, the gist of the present invention is (1) chewing gum containing an egg egg antibody as an active ingredient for the prevention of infectious diseases, (2) an antibody against a microorganism causing causative infection in the oral cavity, an antibody against a respiratory tract or respiratory tract infection. The chewing gum according to (1) above, which is one or more selected from the group consisting of an antibody against a causative microorganism and an antibody against a causative microorganism of a digestive tract infection, and (3) a chicken egg antibody which is an active ingredient for preventing respiratory diseases. Chewing gum contained as (4)
(3) The chewing gum according to (3) above, wherein the chicken egg antibody is an antibody against an allergen of a respiratory disease, and (5) the above (1) to (4), which contains 0.01 to 10% by weight of a chicken egg antibody as a pure product. ) Chewing gum according to any one of the above.
【0010】[0010]
【発明の実施の形態】本発明のチューインガムは、鶏卵
抗体を感染症予防又は呼吸器系疾患予防の有効成分とし
て含有するものである。本発明において予防の対象とな
る感染症としては、例えば、口腔内感染症、気管又は気
道感染症及び消化管感染症等が挙げられる。さらに本発
明において予防の対象となる呼吸器系疾患としては、ア
レルギーによるものが挙げられる。そこで、本発明は、
上記感染症の原因である微生物(細菌、マイコプラズ
マ、及びウイルス等)に対する鶏卵抗体、又は呼吸器系
疾患のアレルゲンに対する鶏卵抗体をチューインガムに
含有させることにより、上記感染症又は呼吸器系疾患の
予防を達成させるものである。上記感染症の原因微生物
及び呼吸器系疾患のアレルゲンの具体例について以下に
説明する。BEST MODE FOR CARRYING OUT THE INVENTION The chewing gum of the present invention contains a chicken egg antibody as an active ingredient for the prevention of infectious diseases or respiratory diseases. Examples of infectious diseases to be prevented in the present invention include oral infection, tracheal or respiratory tract infection, and digestive tract infection. Further, examples of respiratory diseases to be prevented in the present invention include allergic diseases. Therefore, the present invention
Prevention of the infectious disease or respiratory disease by including chicken egg antibody against the microorganism (bacteria, mycoplasma, virus, etc.) that causes the infectious disease, or egg antibody against the allergen of respiratory disease, in the chewing gum. To achieve. Specific examples of the causative microorganisms of the infectious diseases and the allergens of respiratory diseases will be described below.
【0011】本発明における口腔内感染症の原因菌とし
ては、う蝕の主な原因菌であるストレプトコッカス・ミ
ュータンス(S.mutans)、及び歯周病の原因菌(例え
ば、バクテロイデス・ジンジバリウス、アクチノバチル
ス・アクチノマイセテムコミタンス、フゾバクテリウム
・ヌクレエイタム(Fusobacterium nucleatum )、アク
チノマイセス・ビスコーサス及びバクテロイデス・メラ
ニノゲニクス・サブスピーシーズ・メラニノゲニクス
(Bacteroides melaninogenicus subsp. melaninogenic
us)等)等が挙げられる。また、口腔内感染症の原因ウ
イルスとしては、単純ヘルペスウイルス(herpessimple
x virus)、水痘−帯状疱疹ウイルス(varicella-zoste
r virus)、サイトメガロウイルス(cytomegalo viru
s)、エプスタイン・バーウイルス(epstein-barr viru
s, EB virus)、コクサロキーウイルス(coxsackie vi
rus)、ムンプスウイルス(mumpus virus)、麻疹ウイ
ルス(measles virus)、ヒト免疫不全ウイルス(huma
n immunodeficiency virus)、及びB型肝炎ウイルス
(hepatitis B virus)等が挙げられる。As the causative bacterium of the oral infection in the present invention, Streptococcus mutans (S. mutans), which is a main causative bacterium of dental caries, and causative bacterium of periodontal disease (eg, Bacteroides gingivalius, Actino) Bacteroides melaninogenicus subsp. Melaninogenic.
us) etc.) and the like. The herpes simplex virus (herpessimple virus) is a virus that causes oral infections.
x virus), chickenpox-zoster virus (varicella-zoste
r virus), cytomegalo viru
s), Epstein-Barr virus (epstein-barr viru
s, EB virus), coxsackie vi
rus), mumps virus, measles virus, human immunodeficiency virus (huma)
n immunodeficiency virus) and hepatitis B virus (hepatitis B virus).
【0012】本発明における気管又は気道感染症の原因
菌としては、スタフィロコッカス・アウレウス(Staphy
lococcus aureus )等のグラム陽性菌、クレブシーラsp
p (Klebsiella spp)等の好気性グラム陰性桿菌等が挙
げられる。更に、マイコプラズマ・ニューモニエ(Myco
plasma pneumoniae )、コキシーラ・ブルネッティイ
(Coxiella burnetii )等のマイコプラズマやリケッチ
ア等も挙げられる。また、気管又は気道感染症の原因ウ
イルスとしては、インフルエンザウイルスA、B及びC
型、パラインフルエンザウイルス1、2及び3型、RS
ウイルス、アデノウイルス、ライノウイルス、コロナウ
イルス、EBウイルス、単純ヘルペスウイルス、麻疹ウ
イルス、水痘ウイルス、エコーウイルス及びコクサツキ
ーウイルス等が挙げられる。As a causative bacterium of tracheal or respiratory tract infection in the present invention, Staphylococcus aureus (Staphy
Klebsiella sp., Gram-positive bacteria such as lococcus aureus)
Aerobic gram-negative bacilli such as p (Klebsiella spp) and the like can be mentioned. Furthermore, Mycoplasma pneumoniae (Myco
Plasma pneumoniae), mycoplasma such as Coxiella burnetii, rickettsia and the like are also included. In addition, as the causative virus of tracheal or respiratory tract infection, influenza viruses A, B and C
Type, parainfluenza virus types 1, 2 and 3, RS
Virus, adenovirus, rhinovirus, coronavirus, EB virus, herpes simplex virus, measles virus, varicella virus, echo virus, Coxsackie virus and the like can be mentioned.
【0013】本発明における消化管感染症の原因菌とし
ては、ヘリコバクター・ピロリー、病原性大腸菌、サル
モネラ菌、ビブリオ菌、ブドウ球菌、ボツリヌス菌及び
ウェルシュ菌等が挙げられる。また、消化管感染症の原
因ウイルスとしては、ロタウイルス、腸性アデノウイル
ス、ノルオウクウイルス、カリシウイルス、アストロウ
イルス、コロナウイルス、ブレダウイルス等が挙げられ
る。Examples of the causative bacteria of the digestive tract infection in the present invention include Helicobacter pylori, pathogenic Escherichia coli, Salmonella, Vibrio, Staphylococcus, Botulinum, and Clostridium bacillus. Examples of viruses that cause gastrointestinal infections include rotavirus, enteric adenovirus, noroku virus, calicivirus, astrovirus, coronavirus, and Bredavirus.
【0014】本発明における呼吸器系疾患のアレルゲン
としては、スギ科、ヒノキ属、松科、イチョウ、ブタク
サ属、マツ属、イネ科、ヨモギ属、カバノキ科、コナラ
属、ギシギシ属、ムカシヨモギ属等の花粉症アレルギー
の原因花粉、及びヒョウダニやユスリカ等の糞、死骸又
は抜け殻等が挙げられる。The allergens for respiratory diseases in the present invention include Cryptomeria, Cypress, Pinus, Ginkgo, Ragweed, Pine, Gramineae, Artemisia, Birchaceae, Quercus, Rumex, Scutellaria and the like. Causes of allergy to hay fever, such as pollen, and feces such as leopard mites and chironomids, carcasses or shells.
【0015】本発明における鶏卵抗体とは、上記の原因
微生物あるいはアレルゲン由来の抗原物質を産卵鶏に免
疫して得られる免疫グロブリンであり、このような鶏卵
抗体は通常行われる公知の方法によって調製できる。よ
り具体的には、例えば以下に説明するような方法によっ
て調製できる。免疫される鶏としては、特に制限はない
が、抗体の産生量の点から、白色レグホン系、ロードア
イランドレッド系、横班プリマスロック系、ニューハン
プシャー系等の卵用種を用いるのが特に好ましい。免疫
方法としては、静脈注射、皮下注射、筋肉注射、腹腔内
投与等、動物に免疫することのできる方法であれば特に
制限はない。抗原物質は、目的とする抗原単品、または
目的に応じて複数の抗原を混合した混合抗原を用いれば
良い。また、抗原物質の投与量は所望の抗体価が得ら
れ、かつ鶏に対して悪影響を与えない程度の量を適宜選
択すれば良い。The hen egg antibody in the present invention is an immunoglobulin obtained by immunizing a laying hen with the above-mentioned causative microorganism or allergen-derived antigenic substance, and such hen egg antibody can be prepared by a commonly known method. . More specifically, it can be prepared, for example, by the method described below. The chicken to be immunized is not particularly limited, but from the viewpoint of the amount of antibody produced, it is particularly preferable to use an egg species such as white leghorn system, Rhode Island red system, lateral plymouth rock system, and New Hampshire system. The immunization method is not particularly limited as long as it can immunize an animal, such as intravenous injection, subcutaneous injection, intramuscular injection, and intraperitoneal administration. As the antigen substance, a single antigen of interest or a mixed antigen in which a plurality of antigens are mixed depending on the purpose may be used. The dose of the antigenic substance may be appropriately selected so that the desired antibody titer is obtained and the chicken is not adversely affected.
【0016】通常、初回免疫後、毎週1回で3〜5回程
度繰り返し投与すると、本発明における抗原物質に特異
的に反応する抗体が卵黄中等に得られる。その後、抗体
価の維持を目的として1〜4ヶ月ごとに追加免疫をする
と良い。また、必要に応じてFCA(フロイント完全ア
ジュバント)、FICA(フロイント不完全アジュバン
ト)、水酸化アルミニウム等のアジュバントを併用して
免疫しても良い。このようにして通常、初回免疫から1
ヶ月以上経過すると、鶏卵中等から十分な抗体価を有す
る抗体を調製することができる。鶏卵中の特異的抗体価
は、酵素免疫測定法(ELISA)、ラジオイムノアッ
セイ、マイクロタイター法等を用いて測定することがで
き、免疫後に2週間程度の間隔で抗体価を測定すること
により抗体価の推移を追跡することができる。[0016] Usually, after the first immunization, the antibody which reacts specifically with the antigenic substance of the present invention is obtained in egg yolk or the like by repeated administration once a week for 3 to 5 times. Then, it is advisable to perform booster immunization every 1 to 4 months for the purpose of maintaining the antibody titer. In addition, if necessary, an immunization may be performed by using an adjuvant such as FCA (Freund's complete adjuvant), FICA (Freund's incomplete adjuvant), and aluminum hydroxide in combination. In this way, usually 1
After a lapse of months or more, an antibody having a sufficient antibody titer can be prepared from chicken eggs or the like. The specific antibody titer in chicken eggs can be measured by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, microtiter method, etc., and the antibody titer can be measured at intervals of about 2 weeks after immunization. The transition of can be tracked.
【0017】チューインガムに加える際の鶏卵抗体の形
態は、必ずしも純粋な免疫グロブリンである必要はな
い。すなわち、鶏卵抗体の部分精製物である抗体含有画
分をチューインガムに加えてもよく、より高純度に精製
された精製鶏卵抗体を加えてもよい。具体的には、上述
のように免疫した鶏卵の卵黄液を粉末化した卵黄粉末、
卵黄液から卵黄リポタンパク質を除去して得られる卵黄
水溶性タンパク質を粉末化した卵黄水溶性タンパク質粉
末、及び卵黄粉末を超臨界抽出により脂質を除去した脱
脂卵黄粉末等をチューインガムに添加してもよい。ま
た、卵黄水溶性タンパク質をイオン交換クロマトグラフ
ィー、疎水性クロマトグラフィー、アフィニティークロ
マトグラフィー、ゲル濾過、硫酸ナトリウム塩析等の公
知のタンパク質精製法により精製して得たものを添加し
てもよい。The form of the hen egg antibody when added to chewing gum does not necessarily have to be pure immunoglobulin. That is, the antibody-containing fraction, which is a partially purified product of the chicken egg antibody, may be added to the chewing gum, or the purified chicken egg antibody purified to a higher purity may be added. Specifically, egg yolk powder obtained by pulverizing the yolk liquid of the chicken egg immunized as described above,
Egg yolk water-soluble protein powder obtained by pulverizing egg yolk water-soluble protein obtained by removing egg yolk lipoprotein from egg yolk liquid, and defatted egg yolk powder obtained by removing lipid from yolk powder by supercritical extraction may be added to chewing gum. . Further, a protein obtained by purifying egg yolk water-soluble protein by a known protein purification method such as ion exchange chromatography, hydrophobic chromatography, affinity chromatography, gel filtration, sodium sulfate salting out may be added.
【0018】さらには卵黄等に含まれる鶏卵抗体、即ち
免疫グロブリンそのものを抽出、分離してこれを添加し
てもよい。免疫グロブリンの抽出、分離方法としては、
例えば、デキストラン硫酸やポリエチレングリコール
(PEG)、寒天、カラギナン、ファーセレラン、ペク
チン、キサンタンガム、アルギン酸、アルギン酸誘導体
等を用いてリポタンパク質を沈澱させ、その上清から分
離、精製する方法(Journal of Immunological Method
s, 46, 63-68, 1981 /Immunological Communication,
9(5), 475-493, 1980/特開昭63−215699号公
報/特開昭64−38098号公報)、超臨界ガスによ
り卵黄脂質を抽出除去した脱脂卵黄粉末やプロパノー
ル、クロロホルム、イソピルアルコール、エタノール等
を用いた抽出法など通常、免疫グロブリンの抽出、分離
に用いられる公知の種々の方法が用いられる。これらの
方法の中で、本発明における抗体の食品分野への利用を
考慮して、カラギナン、キサンタンガム、ペクチン等の
食品添加物として認められているものを用いる方法が人
体への安全性の見地から好ましい。Furthermore, the hen's egg antibody contained in egg yolk or the like, that is, the immunoglobulin itself may be extracted and separated and added. As the method for extracting and separating immunoglobulins,
For example, a method of precipitating lipoprotein using dextran sulfate, polyethylene glycol (PEG), agar, carrageenan, furceleran, pectin, xanthan gum, alginic acid, alginic acid derivative, etc., and separating and purifying from the supernatant (Journal of Immunological Method
s, 46, 63-68, 1981 / Immunological Communication,
9 (5), 475-493, 1980 / JP-A-63-21569 / JP-A-64-38098), defatted egg yolk powder obtained by extracting and removing egg yolk lipids with supercritical gas, propanol, chloroform, and isopropyl. Various known methods commonly used for immunoglobulin extraction and separation are used, such as extraction methods using alcohol, ethanol and the like. Among these methods, in consideration of the use of the antibody in the present invention in the food field, carrageenan, xanthan gum, a method using an approved food additive such as pectin, from the viewpoint of safety to the human body. preferable.
【0019】このようにして得られた各種調製サンプル
の鶏卵抗体の純度は、当該サンプルの粉末重量に対する
鶏卵抗体重量で算出すると、卵黄粉末の形態では通常鶏
卵抗体が1〜2重量%、脱脂卵黄粉末の形態では通常2
〜8重量%、卵黄水溶性タンパク質粉末の形態では通常
8〜12重量%、精製鶏卵抗体(上記公知のタンパク質
精製法によるもの)では通常95重量%以上である。The hen egg antibody purity of the various prepared samples thus obtained is calculated by the hen egg antibody weight relative to the powder weight of the sample. In the egg yolk powder form, the hen egg antibody is usually 1 to 2% by weight and the defatted egg yolk. Usually 2 in powder form
-8% by weight, usually 8-12% by weight in the form of egg yolk water-soluble protein powder, and usually 95% by weight or more for purified chicken egg antibody (by the above-mentioned known protein purification method).
【0020】本発明のチューインガムは、味ガムおよび
風船ガムのいずれのチューインガムであっても良い。本
発明のチューインガムにおけるガムベースの配合とガム
配合は、従来の配合方法に準ずれば良い。ガムベースの
配合原料としては、天然樹脂、酢酸ビニル樹脂、エステ
ルガム、合成ガム、天然ワックス、乳化剤、及び炭酸カ
ルシウム等が挙げられ、これらを上記のチューインガム
の種類に応じて選択し、配合する。The chewing gum of the present invention may be either a chewing gum of taste gum or bubble gum. The composition of the gum base and the composition of the gum in the chewing gum of the present invention may be based on the conventional compounding method. Examples of the gum base compounding raw materials include natural resins, vinyl acetate resins, ester gums, synthetic gums, natural waxes, emulsifiers, and calcium carbonate. These are selected and compounded according to the type of chewing gum described above.
【0021】ガムベースの配合例は、例えば次の通りで
ある。味ガムベースでは、天然樹脂10〜30重量%、
酢酸ビニル樹脂10〜30重量%、合成ゴム10〜30
重量%、エステルガム5〜20重量%、ワックス類10
〜40重量%、乳化剤1〜10重量%及び充填剤5〜2
0重量%等の割合で使用される。風船ガムベースでは、
酢酸ビニル樹脂10〜40重量%、合成ゴム10〜30
重量%、エステルガム5〜20重量%、ワックス類10
〜40重量%、乳化剤5〜20重量%及び充填剤5〜2
0重量%等の割合で使用される。これらのガムベースに
砂糖、ブドウ糖、水飴等の糖類、栄養素および香料など
を加え、常法により混合される。香料としては天然香
料、合成香料などの油脂香料が適当であるが、特に限定
されない。例えばミント系香料(ペパーミント、スペア
ミント、メントール等)、フルーツ系香料(シトラス、
ミックスフルーツ、ストロベリー、グレープ、チェリー
等)、スパイス系香料(シナモン、クロープ、アネトー
ル、リコリス、シソ、ローズマリ他)等が挙げられる。[0021] Examples of the composition of the gum base are as follows. In the taste gum base, 10 to 30% by weight of natural resin,
Vinyl acetate resin 10-30% by weight, synthetic rubber 10-30
% By weight, ester gum 5-20% by weight, waxes 10
-40% by weight, emulsifier 1-10% by weight and filler 5-2
It is used in a proportion such as 0% by weight. In bubble gum base,
Vinyl acetate resin 10-40% by weight, synthetic rubber 10-30
% By weight, ester gum 5-20% by weight, waxes 10
-40 wt%, emulsifier 5-20 wt% and filler 5-2
It is used in a proportion such as 0% by weight. Sugar, glucose, saccharides such as starch syrup, nutrients and flavors are added to these gum bases and mixed by a conventional method. Suitable fragrances are fats and oils such as natural fragrances and synthetic fragrances, but are not particularly limited. For example, mint flavors (peppermint, spearmint, menthol, etc.), fruit flavors (citrus,
Mixed fruits, strawberries, grapes, cherries, etc.), spice-based flavors (cinnamon, clove, anethole, licorice, perilla, rosemary, etc.) and the like.
【0022】チューインガムの製造工程は、公知の方法
に従って良い。例えば、一般にガムの原料を混合練成し
(ガム仕上がり温度40〜60℃)、適宜の厚さと幅で
押し出し、ロール圧延後、冷却、裁断、熟成などの工程
によって製造される。The production process of chewing gum may follow a known method. For example, generally, it is manufactured by mixing and kneading raw materials of gum (gum finishing temperature of 40 to 60 ° C.), extruding to an appropriate thickness and width, rolling after rolling, cooling, cutting, aging and the like.
【0023】本発明のチューインガムは、上記のような
ガムの配合物と共に鶏卵抗体が含有されていれば良い
が、その添加方法としては、例えば、鶏卵抗体を粉末状
または水に分散させて添加する方法、鶏卵抗体を水に加
え高速攪拌して粘稠な分散液として添加する方法、鶏卵
抗体と水との分散液を50〜65℃に加熱した後添加す
る方法等が好適な方法として挙げられる。なかでも、鶏
卵抗体を粉末状態で添加する方法が原料投入における操
作及び抗体の安定性の点から最も好ましい。鶏卵抗体の
添加時期としては特に限定されないが、混合練成工程終
了までに添加しておくのが好ましい。より具体的には、
ガムベース、香料または糖類などの副原料に予め混合し
ておいても良いし、ガム製造時に配合しても良い。The chewing gum of the present invention may contain the egg egg antibody together with the above gum composition, and the addition method thereof is, for example, adding the egg egg antibody in the form of powder or dispersed in water. Suitable methods include a method, a method in which an egg egg antibody is added to water and stirred at high speed to add a viscous dispersion, and a method in which a chicken egg antibody and water dispersion is heated to 50 to 65 ° C. and then added. . Among them, the method of adding the egg egg antibody in a powder state is the most preferable from the viewpoint of the operation in charging the raw materials and the stability of the antibody. The timing of adding the egg egg antibody is not particularly limited, but it is preferable to add it by the end of the mixing and kneading step. More specifically,
It may be mixed in advance with an auxiliary material such as a gum base, a flavoring agent or a sugar, or may be blended at the time of manufacturing the gum.
【0024】鶏卵抗体は前記のように部分精製物を添加
してもよいが、この場合、その配合量が多いと卵黄由来
の臭気が問題になることが懸念される。しかし、本発明
においては純品換算で極めて微量の配合でも有効な抗体
活性が認められるので、部分精製物を用いることに特に
問題はない。即ち、鶏卵抗体はチューインガム製品中、
純品換算で0.01重量%以上、好ましくは0.01〜
10重量%、特に好ましくは0.1〜5重量%配合すれ
ば良い。また、鶏卵抗体は、一の抗原に対する抗体の一
成分のみでもよく、二成分以上であってもよい。A partially purified product may be added to the chicken egg antibody as described above, but in this case, if the blending amount is large, there is a concern that the odor derived from egg yolk becomes a problem. However, in the present invention, effective antibody activity is recognized even in an extremely small amount as a pure product, so there is no particular problem in using the partially purified product. That is, the chicken egg antibody is a chewing gum product,
0.01% by weight or more in terms of pure product, preferably 0.01 to
10 wt%, and particularly preferably 0.1 to 5 wt% may be added. Further, the hen egg antibody may have only one component of the antibody against one antigen, or may have two or more components.
【0025】本発明のチューインガムには、製造時の温
度が比較的低温(30〜55℃)であるため、抗体活性
を失活させることなく抗体を含有させることができる。
また、チューインガムの咀嚼時間は他の食品等に比較し
て長時間であるため、鶏卵抗体の効果を長時間発揮させ
ることができる。さらには、特に口腔内感染症において
は、チューインガム基材が歯面や歯茎に付着した口腔内
感染菌を物理的に剥がし落とし、再付着を予防する効果
がある。Since the chewing gum of the present invention is manufactured at a relatively low temperature (30 to 55 ° C.), it can contain an antibody without deactivating the antibody activity.
Moreover, since the chewing gum has a longer chewing time than other foods, the effect of the egg egg antibody can be exerted for a long time. Furthermore, particularly in oral infections, the chewing gum base material has an effect of physically peeling off the infectious bacteria in the oral cavity adhering to the tooth surface and gums to prevent reattachment.
【0026】[0026]
【実施例】以下、製造例、実施例、比較例及び試験例に
より本発明をさらに詳しく説明するが、本発明はこれら
の実施例等によりなんら限定されるものではない。 製造例1.鶏卵抗体の調製 GAMブイヨン培地(日水製薬(株)製)でバクテロイ
デス・ジンジバリウスGAI7802を培養後、同菌を
0.5%ホルマリンで常法に従い不活化し、ワクチンと
した。産卵鶏をこの不活化ワクチン(1×109 菌数/
ml)で過免疫し(1ml、筋肉注射×4回)、バクテ
ロイデス・ジンジバリウスに対する特異的抗体を含有す
る鶏卵を得た。EXAMPLES The present invention will be described in more detail with reference to production examples, examples, comparative examples and test examples, but the present invention is not limited to these examples. Production Example 1. Preparation of chicken egg antibody After culturing Bacteroides gingivalius GAI7802 in GAM broth medium (manufactured by Nissui Pharmaceutical Co., Ltd.), the bacterium was inactivated with 0.5% formalin according to a conventional method to give a vaccine. Laying chickens with this inactivated vaccine (1 x 10 9 bacteria /
ml) hyperimmunized (1 ml, intramuscular injection x 4 times) to obtain chicken eggs containing a specific antibody against Bacteroides gingivalius.
【0027】このようにして得られた鶏卵の卵黄に等量
の水を加え均質化し、卵黄希釈液とした。卵黄希釈液1
容量と1mg/ml濃度のλ−カラギーナン水溶液5容
量を混合し、生じるリポタンパク質の凝集物を遠心分離
により除去した。こうして得られた上清は約80%の回
収率で鶏卵抗体を含んでいた。この上清液より硫酸ナト
リウムを用いた塩析法にて鶏卵抗体の精製を行った。鶏
卵抗体は17%(W/V)硫酸ナトリウム濃度で塩析物
として得られ、他の不純物は遠心上清として除去され
た。こうして得られた鶏卵抗体は、10μgで抗原とし
て用いた上記歯周病原因菌1×109 個を凝集する力価
を示した。上記塩析物を10mMリン酸バッファーに対
して透析し、凍結乾燥を行った。このものを、「精製鶏
卵抗体」とする。なお、精製鶏卵抗体の純度は、粉末重
量に対する鶏卵抗体重量で算出すると、98重量%であ
った。The egg yolk thus obtained was homogenized by adding an equal amount of water to obtain an egg yolk diluted solution. Egg yolk diluent 1
The volume was mixed with 5 volumes of a 1 mg / ml concentration λ-carrageenan aqueous solution, and the resulting lipoprotein aggregates were removed by centrifugation. The supernatant thus obtained contained chicken egg antibody with a recovery rate of about 80%. The egg yolk antibody was purified from this supernatant by a salting-out method using sodium sulfate. The chicken egg antibody was obtained as a salted out product at a concentration of 17% (W / V) sodium sulfate, and other impurities were removed as a centrifugal supernatant. The thus-obtained chicken egg antibody showed a titer of agglutinating 1 × 10 9 of the periodontal disease-causing bacteria used as an antigen at 10 μg. The salted-out product was dialyzed against 10 mM phosphate buffer and freeze-dried. This is referred to as "purified chicken egg antibody". The purity of the purified chicken egg antibody was 98% by weight calculated by the weight of the chicken egg antibody based on the weight of the powder.
【0028】実施例1.鶏卵抗体含有チューインガムの
作製 製造例1で調製した精製鶏卵抗体を0.5重量%(純品
換算で0.49重量%)配合したチューインガムを作製
した。以下処方を示す。 Embodiment 1 FIG. Preparation of Chicken Egg Antibody-Containing Chewing Gum A chewing gum containing the purified chicken egg antibody prepared in Production Example 1 in an amount of 0.5% by weight (0.49% by weight in terms of pure product) was prepared. The prescription is shown below.
【0029】ガムベースを二重釜に入れ約120℃にて
溶解攪拌し、50℃まで温度を下げた後に混合機に投入
した。混合機に移されたガムベースに砂糖、次いでブド
ウ糖、水飴、グリセリン、香料、精製鶏卵抗体の順で投
入し、同温度で45分間攪拌した。精製鶏卵抗体は、原
料投入順として最後に粉末の状態で添加した。よく混合
後、射出成形機に入れブロック状に押し出し、更にロー
ルにかけて徐々に圧延し、裁断機により裁断した。これ
により、一粒5gの鶏卵抗体含有チューインガムを得
た。The gum base was placed in a double kettle, dissolved and stirred at about 120 ° C., cooled to 50 ° C., and then charged into a mixer. Sugar, then glucose, starch syrup, glycerin, flavor, and purified chicken egg antibody were sequentially added to the gum base transferred to the mixer, and stirred at the same temperature for 45 minutes. The purified chicken egg antibody was added as a powder at the end in the order of raw material addition. After mixing well, the mixture was put into an injection molding machine, extruded in a block shape, further rolled and gradually rolled, and then cut by a cutting machine. As a result, 5 g of a chicken egg antibody-containing chewing gum was obtained.
【0030】比較例1.鶏卵抗体含有キャンディーの作
製 製造例1で調製した精製鶏卵抗体を0.5重量%配合し
たキャンディーを作製した。以下処方を示す。 Comparative Example 1 Preparation of candy containing egg egg antibody A candy containing 0.5% by weight of the purified egg egg antibody prepared in Production Example 1 was prepared. The prescription is shown below.
【0031】砂糖、水飴及び水を鍋に加え煮沸し、煮沸
温度が125℃に到達した後に攪拌しながら練乳を加え
た。その後、攪拌しながら更に煮沸し、煮沸温度が13
0℃に達した後にバターを加えた。引き続き煮沸を行い
温度が130℃に到達した後、火から下ろしバニラエッ
センス及び精製鶏卵抗体を添加した。精製鶏卵抗体は粉
末の状態で添加した。その後攪拌を行い冷却盤に流し込
んだ。約80℃にまで下げた後、棒状にし、適当な長さ
に切断した。これにより、一粒重量5gの鶏卵抗体含有
キャンディーを得た。Sugar, starch syrup and water were added to a pan and boiled. After the boiling temperature reached 125 ° C., condensed milk was added with stirring. Then, boil further with stirring, and the boiling temperature is 13
Butter was added after reaching 0 ° C. After boiling was continued and the temperature reached 130 ° C., the mixture was removed from the heat, vanilla extract and purified chicken egg antibody were added. The purified chicken egg antibody was added in the form of powder. Then, the mixture was stirred and poured into a cooling plate. After the temperature was lowered to about 80 ° C., it was made into a rod shape and cut into an appropriate length. As a result, a hen egg antibody-containing candy having a weight of 5 g was obtained.
【0032】比較例2.鶏卵抗体含有ラムネ菓子の作製 製造例1で調製した精製鶏卵抗体を0.5重量%配合し
たラムネ菓子を作製した。以下、処方を示す。 Comparative Example 2 Preparation of chicken egg antibody-containing Ramune confectionery A Ramune cake containing 0.5% by weight of the purified chicken egg antibody prepared in Production Example 1 was prepared. The prescription is shown below.
【0033】L−酒石酸、重曹、アスパルテーム、香
料、色素、シュガーエステルを混合し、乳糖を用いて造
粒を行った。造粒品温度が約40℃になるまで冷却した
後、精製鶏卵抗体を添加し、混合した。打錠機を用いて
20mm碁石R杵で1cm2 当たり1トンの圧力で打錠
を行った。これにより、一粒重量1.5gの鶏卵抗体含
有ラムネ菓子を得た。L-tartaric acid, baking soda, aspartame, fragrance, pigment and sugar ester were mixed and granulated with lactose. After cooling the granulated product to a temperature of about 40 ° C., the purified chicken egg antibody was added and mixed. Tableting was performed using a tableting machine with a 20 mm Goishi R punch at a pressure of 1 ton per cm 2 . Thereby, a ramune confectionery containing an egg antibody having a grain weight of 1.5 g was obtained.
【0034】比較例3.鶏卵抗体含有チョコレートの作
製 製造例1で調製した精製鶏卵抗体を0.5重量%配合し
たチョコレートを作製した。以下処方を示す。 Comparative Example 3. Preparation of Chicken Egg Antibody-Containing Chocolate A chocolate containing 0.5% by weight of the purified egg egg antibody prepared in Production Example 1 was prepared. The prescription is shown below.
【0035】チョコレート作製は常法に従い、まずカカ
オマス、カカオ脂、粉糖、レシチン、全脂粉乳をミキサ
ーで混合し、リファイニング及びコーチング終了後、テ
ンパリング工程において、チョコレート品温度40℃で
精製鶏卵抗体粉末を添加し、均質化した。精製鶏卵抗体
は粉末の状態で添加した。その後、型流し・冷却工程を
経て、板チョコレートを作製した。この板チョコレート
を5gの大きさに分割し、鶏卵抗体含有チョコレートを
得た。Chocolate production is carried out according to a conventional method. First, cocoa mass, cocoa butter, powdered sugar, lecithin and whole milk powder are mixed with a mixer, and after refining and coating, in a tempering step, purified chocolate egg antibody at a temperature of 40 ° C. Powder was added and homogenized. The purified chicken egg antibody was added in the form of powder. Then, a plate chocolate was produced through a casting and cooling process. This plate chocolate was divided into 5 g pieces to obtain a chicken egg antibody-containing chocolate.
【0036】試験例1.鶏卵抗体含有菓子中の抗体活性
の測定 実施例1で作製したチューインガム、比較例1で作製し
たキャンディー、比較例2で作製したラムネ菓子、及び
比較例3で作製したチョコレート中の鶏卵抗体の抗体活
性を、バクテロイデス・ジンジバリウスに対する抗菌活
性を測定することにより求めた。Test Example 1. Measurement of antibody activity in chicken egg antibody-containing confectionery Chewing gum prepared in Example 1, candy prepared in Comparative Example 1, ramune confectionery prepared in Comparative Example 2, and antibody activity of chicken egg antibody in chocolate prepared in Comparative Example 3 Was determined by measuring the antibacterial activity against Bacteroides gingivalius.
【0037】まず、各菓子中から鶏卵抗体を回収した。
実施例1で作製したチューインガムからの鶏卵抗体の回
収は、鶏卵抗体含有チューインガムを乳鉢にて抽出する
ことにより行った。即ち、鶏卵抗体含有チューインガム
5gを乳鉢にて5mlの生理食塩水で5分間こね、抽出
液を得た。同操作を3回繰り返した後、抽出液を集めチ
ューインガム重量の100倍にメスアップし、これをチ
ューインガム抽出液とした。この抽出液のpHを測定し
たところ、pHは7.2であった。First, the chicken egg antibody was recovered from each confectionery.
The chicken egg antibody was recovered from the chewing gum prepared in Example 1 by extracting the chicken egg antibody-containing chewing gum in a mortar. That is, 5 g of chicken egg antibody-containing chewing gum was kneaded with 5 ml of physiological saline in a mortar for 5 minutes to obtain an extract. After the same operation was repeated 3 times, the extracts were collected and the amount of the chewing gum was adjusted to 100 times the weight of the chewing gum to obtain a chewing gum extract. When the pH of this extract was measured, the pH was 7.2.
【0038】比較例1で作製したキャンディーからの鶏
卵抗体の回収は、鶏卵抗体含有キャンディーを生理食塩
水に溶解することにより行った。即ち、鶏卵抗体含有キ
ャンディーを粉砕後、重量の100倍量の生理食塩水に
溶解し、このものをキャンディー液とした。このキャン
ディー液のpHを測定したところ、pHは7.5であっ
た。比較例2で作製したラムネ菓子中からの鶏卵抗体の
回収は、鶏卵抗体含有ラムネ菓子を生理食塩水に溶解す
ることにより行った。即ち、鶏卵抗体含有ラムネ菓子重
量の100倍量の生理食塩水に溶解し、これをラムネ菓
子液とした。ラムネ菓子液のpHを測定したところ、p
Hは2.3であった。比較例3で作製したチョコレート
中からの鶏卵抗体の回収は、鶏卵抗体含有チョコレート
を生理食塩水に溶解することにより行った。即ち、鶏卵
抗体含有チョコレート重量の100倍量の生理食塩水に
溶解し、これをチョコレート液とした。チョコレート液
のpHを測定したところ、pHは7.2であった。The egg egg antibody was recovered from the candy prepared in Comparative Example 1 by dissolving the egg egg antibody-containing candy in physiological saline. That is, the hen egg antibody-containing candy was crushed and then dissolved in 100 times the weight of physiological saline to obtain a candy solution. When the pH of this candy solution was measured, the pH was 7.5. Recovery of the chicken egg antibody from the Ramune confectionery prepared in Comparative Example 2 was performed by dissolving the chicken egg antibody-containing Ramune cake in physiological saline. That is, it was dissolved in 100 times the amount of physiological saline of the egg antibody-containing ramune candy to prepare a ramune candy solution. When the pH of the Ramune confectionery solution was measured, p
H was 2.3. The egg egg antibody was recovered from the chocolate prepared in Comparative Example 3 by dissolving the egg egg antibody-containing chocolate in physiological saline. That is, it was dissolved in 100 times the amount of physiological saline containing the egg antibody-containing chocolate to prepare a chocolate solution. When the pH of the chocolate liquid was measured, the pH was 7.2.
【0039】次に各溶液の抗菌活性を調べた。それぞれ
の溶液をGAMブイヨン培地(5ml)へ100ppm
の濃度に添加し、バクテロイデス・ジンジバリウスGA
I7802菌を初発菌数1.0×10 5 /mlとなるよ
うに加え、37℃で嫌気的に培養し、3、6、9日目の
生菌数をGAM寒天培地で測定した。その結果を表1に
示す。なお、対照として50μg/mlの精製鶏卵抗体
溶解液を菓子溶液の代わりに用い、同様に操作した。Next, the antibacterial activity of each solution was examined. Respectively
100 ppm of the above solution to GAM broth medium (5 ml)
Bacteroides gingivalius GA
I7802 bacterium initial number of bacteria 1.0 × 10 Five/ Ml
Sea urchin, anaerobically cultivated at 37 ℃,
The viable cell count was measured on a GAM agar medium. The results are shown in Table 1.
Show. As a control, 50 μg / ml of purified chicken egg antibody
The dissolution solution was used instead of the confectionery solution, and the same operation was performed.
【0040】[0040]
【表1】 [Table 1]
【0041】表1に示されるように、キャンディー及び
ラムネ菓子に比べ、チューインガム及びチョコレートに
添加した鶏卵抗体はバクテロイデス・ジンジバリウスに
対してより高い抗菌活性を示した。これは、菓子製造時
の温度が高温であったり、菓子溶液が強酸性であったた
め、活性が失活したものと考えられる。一方、チューイ
ンガム及びチョコレートの抗菌活性は対照とほぼ同じで
あり、抗体活性はチューインガム及びチョコレートの製
造時の処理によっては失活しないことが示された。As shown in Table 1, the egg yolk antibody added to chewing gum and chocolate showed higher antibacterial activity against Bacteroides gingivalius as compared to candy and Ramune confectionery. It is considered that the activity was deactivated because the temperature during the manufacture of the confectionery was high and the confectionery solution was strongly acidic. On the other hand, the antibacterial activity of chewing gum and chocolate was almost the same as the control, indicating that the antibody activity was not inactivated by the treatment during the production of chewing gum and chocolate.
【0042】試験例2.口腔内の鶏卵抗体活性の持続性
の確認 鶏卵抗体を含有したチューインガム及びチョコレートを
咀嚼し、口腔内に溶出される鶏卵抗体活性の持続性を比
較した。被験者(10人)を2群に分け、1つの群には
鶏卵抗体含有チューインガム(5g)を、もう一方の群
には鶏卵抗体含有チョコレート(5g)を与え、咀嚼を
行わせた。咀嚼開始3、5、15、30及び45分後の
被験者の口腔内の唾液を採取し、唾液中に溶出されたバ
クテロイデス・ジンジバリウスに対する抗菌活性を調べ
た。なお、チューインガムの咀嚼時間は30分間継続し
たが、チョコレートの咀嚼時間は3分間程度であった。
各時点における唾液1mlを採取し、滅菌生理食塩水で
5mlにメスアップを行い、55℃で30分間加熱し
た。その後、各唾液をGAMブイヨン培地(5ml)へ
100ppmの濃度に含有し、バクテロイデス・ジンジ
バリウスGAI7802菌を初発菌数1.0×105 /
mlとなるように加え、37℃で嫌気的に培養した。培
養3日目の生菌数をGAM寒天培地で測定した。その結
果を表2に示す。Test Example 2. Confirmation of persistence of egg egg antibody activity in the oral cavity Chewing gum and chocolate containing the egg egg antibody were chewed to compare the persistence of egg egg antibody activity eluted in the oral cavity. The test subjects (10 persons) were divided into two groups, one group was given the egg antibody-containing chewing gum (5 g), and the other group was given the egg antibody-containing chocolate (5 g) to chew them. The saliva in the oral cavity of the subject was sampled at 3, 5, 15, 30 and 45 minutes after the start of mastication, and the antibacterial activity against Bacteroides gingivalius dissolved in the saliva was examined. The chewing gum chewing time continued for 30 minutes, but the chocolate chewing time was about 3 minutes.
1 ml of saliva at each time point was collected, the volume was adjusted to 5 ml with sterile physiological saline, and heated at 55 ° C. for 30 minutes. Then, each saliva was added to GAM broth medium (5 ml) at a concentration of 100 ppm, and the initial number of Bacteroides gingivalius GAI7802 bacteria was 1.0 × 10 5 /
The solution was added to make up to ml, and cultured anaerobically at 37 ° C. The viable cell count on the third day of culture was measured on a GAM agar medium. Table 2 shows the results.
【0043】[0043]
【表2】 [Table 2]
【0044】表2に示されるように、チューインガムか
ら得られた唾液のバクテロイデス・ジンジバリウスに対
する抗菌活性は、チョコレートから得られた唾液の同菌
に対する抗菌活性に比較し、長時間その抗菌効果が持続
することが示された。これは、チューインガムが長時間
咀嚼可能であり、また鶏卵抗体が一気に溶出されるので
はなく、徐々に溶出されることを示している。したがっ
て、鶏卵抗体含有チューインガムは鶏卵抗体の効果が長
時間持続するという好ましい性質を有するものであるこ
とが分かった。As shown in Table 2, the antibacterial activity of saliva obtained from chewing gum against Bacteroides gingivalius lasts longer than that of saliva obtained from chocolate. Was shown. This indicates that the chewing gum can be chewed for a long time, and that the egg egg antibody is gradually eluted instead of being eluted at once. Therefore, it was found that the chicken egg antibody-containing chewing gum has a preferable property that the effect of the chicken egg antibody lasts for a long time.
【0045】試験例3.鶏卵抗体含有菓子による口腔内
付着細菌数変化の確認 鶏卵抗体を含有したチューインガム及びチョコレートを
咀嚼し、咀嚼前後の歯面および歯茎に付着しているバク
テロイデス・ジンジバリウスの菌数を比較した。被験者
(10人)を2群に分け、1つの群には鶏卵抗体含有チ
ューインガム(5g)を、もう一方の群には鶏卵抗体含
有チョコレート(5g)を与え、咀嚼を行わせた。被験
者は鶏卵抗体含有菓子を3分間咀嚼し、咀嚼前及び1時
間後の歯面および歯茎に付着している菌を滅菌綿棒によ
り採取した。綿棒を3mlの滅菌生理食塩水により洗浄
し、その生理食塩水中のバクテロイデス・ジンジバリウ
スの菌数を調べた。Test Example 3. Confirmation of changes in the number of bacteria adhering to the oral cavity caused by a confection containing the egg yolk antibody Chewing gum and chocolate containing the egg yolk antibody were chewed and the numbers of Bacteroides gingivalius attached to the tooth surface and gums before and after chewing were compared. The test subjects (10 persons) were divided into two groups, one group was given the egg antibody-containing chewing gum (5 g), and the other group was given the egg antibody-containing chocolate (5 g) to chew them. The test subject chewed the chicken egg antibody-containing confectionery for 3 minutes, and collected the bacteria adhering to the tooth surface and gums before and 1 hour after chewing with a sterile cotton swab. The cotton swab was washed with 3 ml of sterile physiological saline, and the number of Bacteroides gingivalius cells in the physiological saline was examined.
【0046】バクテロイデス・ジンジバリウスの量は、
同菌を抗原として得られた抗体によるELISA法によ
り測定した。以下に具体的な操作を示す。公知の方法に
より得た、バクテロイデス・ジンジバリウスGAI78
02特異的ウサギIgGを96穴ELISAプレート
(ヌンク製)に公知の方法でコーティングした。PBS
−Tween(Na2HPO4 11.7g 、KH2PO4 5.0g 、NaCl 2
3.4g、NaN3 0.2g 、Tween20 0.5mL を1リットルの蒸留
水に溶解したもの、pH7.2)によりウエルを洗浄
後、ブロックエース(雪印乳業(株)製)を100μL
/ウエルで添加し、1時間静置した。PBS−Twee
nで洗浄後、上記生理食塩水を100μL/ウエル添加
し、37℃で2時間静置した。The amount of Bacteroides gingivalius is
It was measured by an ELISA method using an antibody obtained by using the same bacterium as an antigen. The specific operation is shown below. Bacteroides gingivalius GAI78 obtained by a known method
02-specific rabbit IgG was coated on a 96-well ELISA plate (manufactured by Nunc) by a known method. PBS
-Tween (Na 2 HPO 4 11.7 g, KH 2 PO 4 5.0 g, NaCl 2
3.4 g, NaN 3 0.2 g, Tween 20 0.5 mL dissolved in 1 liter of distilled water, pH 7.2) After washing the wells, 100 μL of Block Ace (Snow Brand Milk Products Co., Ltd.)
/ Well and added, and allowed to stand for 1 hour. PBS-Twee
After washing with n, 100 μL / well of the physiological saline was added, and the mixture was allowed to stand at 37 ° C. for 2 hours.
【0047】2次抗体としてアルカリフォスファターゼ
標識バクテロイデス・ジンジバリウス特異的ヤギIgG
(1ステップグルタルアルデヒド法)を4000倍にP
BS−Tweenで希釈し、100μL/ウエル添加
し、37℃で1時間静置した。PBS−Tweenで洗
浄後、0.1%ニトロフェニルホスフェート(シグマ
製)をジエチルエタノールアミンバッファー(ジエチル
エタノールアミン 97mL 、NaN3 0.2g 、MgCl2-6H2O 100
mgを1リットルに溶解したもの、pH9.8)に溶解し
たものを100μL/ウエルに添加し、37℃、30分
間反応を行い、2NNaOHにより反応を停止させた。
反応後の発色の測定は、マイクロプレートリーダー(東
ソー製)により波長403nmで行った。口腔内付着細
菌数の変化は、咀嚼前の吸光度の値を100%として、
咀嚼後の吸光度の変化により表した。その結果を表3に
示す。Bacteroides gingivalius-specific goat IgG labeled with alkaline phosphatase as a secondary antibody
(1 step glutaraldehyde method) 4000 times P
It was diluted with BS-Tween, 100 μL / well was added, and the mixture was allowed to stand at 37 ° C. for 1 hour. After washing with PBS-Tween, 0.1% nitrophenyl phosphate (manufactured by Sigma) was added to diethyl ethanolamine buffer (diethyl ethanolamine 97 mL, NaN 3 0.2 g, MgCl 2 -6H 2 O 100).
What melt | dissolved mg in 1 liter and what melt | dissolved in pH 9.8) were added to 100 microliters / well, and it reacted at 37 degreeC for 30 minutes, and stopped the reaction with 2N NaOH.
The color development after the reaction was measured with a microplate reader (manufactured by Tosoh Corporation) at a wavelength of 403 nm. The change in the number of bacteria adhering to the oral cavity was calculated by setting the absorbance value before chewing to 100%.
It was represented by the change in absorbance after mastication. Table 3 shows the results.
【0048】[0048]
【表3】 [Table 3]
【0049】表3に示されるように、チョコレートに比
較してチューインガムを咀嚼することにより、口腔内の
歯面および歯茎に付着している菌数がより減少すること
が示された。これは、チューインガムの咀嚼により、口
腔内の菌を物理的にはぎ取るという効果も加わったこと
によるものと考えられる。As shown in Table 3, by chewing chewing gum as compared with chocolate, it was shown that the number of bacteria adhering to the tooth surface and gums in the oral cavity was further reduced. It is considered that this is due to the fact that the chewing gum chews the effect of physically stripping the bacteria in the oral cavity.
【0050】試験例4.鶏卵抗体の有効含有量の確認 鶏卵抗体を純品換算で0.005重量%、0.008重
量%、0.01重量%、0.02重量%、及び0.1重
量%含有するチューインガムを、実施例1と同様にして
作製し、これを用いて、試験例3と同様の方法で口腔内
付着細菌数変化を調べた。結果を表4に示す。Test Example 4. Confirmation of effective content of chicken egg antibody Chewing gum containing 0.005% by weight, 0.008% by weight, 0.01% by weight, 0.02% by weight and 0.1% by weight of the egg egg antibody in pure product, It was prepared in the same manner as in Example 1, and using this, the change in the number of bacteria adhering to the oral cavity was examined by the same method as in Test Example 3. The results are shown in Table 4.
【0051】[0051]
【表4】 [Table 4]
【0052】表4より、含有量が0.01重量%以上の
場合は口腔内付着菌数は顕著に減少していた。From Table 4, when the content was 0.01% by weight or more, the number of bacteria adhering to the oral cavity was remarkably reduced.
【0053】[0053]
【発明の効果】本発明のチューインガムは、感染症予防
又は呼吸器系疾患予防の有効成分として含有させた鶏卵
抗体の効果の持続性の長時間化、摂取の容易化、及び失
活の防止を達成できるため、感染症予防又は呼吸器系疾
患予防に効果的である。EFFECTS OF THE INVENTION The chewing gum of the present invention has a long-lasting effect of chicken egg antibody contained as an active ingredient for the prevention of infectious diseases or respiratory diseases, facilitation of ingestion, and prevention of inactivation. Since it can be achieved, it is effective for the prevention of infectious diseases and respiratory diseases.
Claims (5)
含有するチューインガム。1. A chewing gum containing a chicken egg antibody as an active ingredient for the prevention of infectious diseases.
対する抗体、気管又は気道感染症の原因微生物に対する
抗体、及び消化管感染症の原因微生物に対する抗体から
なる群より選ばれる1種以上のものである請求項1記載
のチューインガム。2. A chicken egg antibody which is one or more selected from the group consisting of an antibody against a causative microorganism of an oral infection, an antibody against a causative microorganism of a respiratory tract or respiratory tract infection, and an antibody against a causative microorganism of a digestive tract infection. The chewing gum according to claim 1, wherein
として含有するチューインガム。3. A chewing gum containing a chicken egg antibody as an active ingredient for the prevention of respiratory diseases.
対する抗体である請求項3記載のチューインガム。4. The chewing gum according to claim 3, wherein the chicken egg antibody is an antibody against an allergen of a respiratory disease.
量%含有してなる請求項1〜4いずれか記載のチューイ
ンガム。5. The chewing gum according to any one of claims 1 to 4, which contains 0.01 to 10% by weight of a chicken egg antibody as a pure product.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7196098A JPH0920684A (en) | 1995-07-07 | 1995-07-07 | Chewing gum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7196098A JPH0920684A (en) | 1995-07-07 | 1995-07-07 | Chewing gum |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0920684A true JPH0920684A (en) | 1997-01-21 |
Family
ID=16352194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7196098A Pending JPH0920684A (en) | 1995-07-07 | 1995-07-07 | Chewing gum |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0920684A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999061918A1 (en) * | 1998-05-28 | 1999-12-02 | Stroemberg Nicklas | Method and means for caries prevention and susceptibility detection |
AU733107B2 (en) * | 1997-03-20 | 2001-05-10 | Immunsystem Ims Ab | Use of avian antibodies |
JP2007145808A (en) * | 2005-11-01 | 2007-06-14 | Asama Chemical Co Ltd | Tablet candy and tablet having new function and method for producing them |
JP2012036154A (en) * | 2010-08-11 | 2012-02-23 | Goshu Yakuhin Kk | Food |
CN103520719A (en) * | 2013-10-24 | 2014-01-22 | 哈德逊(天津)生物技术有限责任公司 | Buccal antibody product and preparation method for same |
JP2014103903A (en) * | 2012-11-28 | 2014-06-09 | J-Farm Co Ltd | Egg antibody inclusion candy and production method of egg antibody inclusion candy |
JP2015105266A (en) * | 2013-12-02 | 2015-06-08 | オーストリッチファーマ株式会社 | Allergen antibody, composition having the same, and filter having antibody |
-
1995
- 1995-07-07 JP JP7196098A patent/JPH0920684A/en active Pending
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU733107B2 (en) * | 1997-03-20 | 2001-05-10 | Immunsystem Ims Ab | Use of avian antibodies |
US6537550B1 (en) | 1997-03-20 | 2003-03-25 | Immun System I.M.S. Ab | Use of avian antibodies |
EP0971741B1 (en) * | 1997-03-20 | 2004-05-26 | Immun System I.M.S. AB | Use of avian antibodies |
WO1999061918A1 (en) * | 1998-05-28 | 1999-12-02 | Stroemberg Nicklas | Method and means for caries prevention and susceptibility detection |
JP2007145808A (en) * | 2005-11-01 | 2007-06-14 | Asama Chemical Co Ltd | Tablet candy and tablet having new function and method for producing them |
JP2012036154A (en) * | 2010-08-11 | 2012-02-23 | Goshu Yakuhin Kk | Food |
JP2014103903A (en) * | 2012-11-28 | 2014-06-09 | J-Farm Co Ltd | Egg antibody inclusion candy and production method of egg antibody inclusion candy |
CN103520719A (en) * | 2013-10-24 | 2014-01-22 | 哈德逊(天津)生物技术有限责任公司 | Buccal antibody product and preparation method for same |
JP2015105266A (en) * | 2013-12-02 | 2015-06-08 | オーストリッチファーマ株式会社 | Allergen antibody, composition having the same, and filter having antibody |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0748591B1 (en) | Fluorinated micellar casein | |
CA2565889C (en) | Oral flora-improving agent, antibacterial agent and growth promoter | |
GB2167299A (en) | Dental caries-preventive composition | |
JPH0920684A (en) | Chewing gum | |
JP2011184300A (en) | Immunoglobulin a secretion-promoter | |
JP2007082469A (en) | Oral-care food and drink | |
JP3072353B2 (en) | Food for preventing gastritis, stomach or duodenal ulcer | |
JP2001017122A (en) | Food for preventing inflammation of digestive system | |
JP4982629B2 (en) | Antibody and anti-periodontal disease composition containing antibody | |
JPH0421648B2 (en) | ||
JPH07116059B2 (en) | Anti-periodontal disease composition | |
JPS60146834A (en) | Production of antibody for inhibiting periodontitis and noncarious composition containing said antibody | |
JP2689511B2 (en) | Food | |
JPH04103539A (en) | Whitened egg yolk containing specific antibody and specific antibody-containing composition | |
JP2014159481A (en) | Immunoglobulin a secretion-promoter | |
CN109593129B (en) | Yolk antibody for preventing dental caries, preparation method thereof and yolk antibody preparation | |
CN107530305B (en) | Mucosal immune activator | |
KR100627635B1 (en) | Production of mammary secretion antibodies in farm animals | |
KR101896123B1 (en) | Immunoglobulin a secretion promoter | |
JPS6315247B2 (en) | ||
JP2008247750A (en) | Anticarious composition | |
JPH03279398A (en) | Antibody and anticarious composition containing same antibody as active ingredient | |
JP3597784B2 (en) | Peptic ulcer inhibitory composition and food and drink containing it | |
JP2666211B2 (en) | Antibody and method for producing anti-caries agent containing the same as an active ingredient | |
DE2522999A1 (en) | Anticaries agent contg. cows milk immunoglobulin - produced by immunizing cows with Streptococcus mutans and isolating |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041005 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050214 |